Comorbidities are prevalent and detrimental for employment outcomes in people of working age with multiple sclerosis

Abstract

Background:

More work is needed to understand the burden of comorbidities in people with multiple sclerosis (MS).

Objective:

To assess prevalence of 30 comorbidities and impacts of comorbidities on employment outcomes in a working-aged MS cohort.

Methods:

Participants were from the Australian MS Longitudinal Study (n = 929). Information on specific comorbidity was obtained (whether or not each was present, doctor-diagnosed, limited their activities and being treated).

Results:

Comorbidities most frequently reported to limit activities were osteoarthritis (51%), migraines (40%), anxiety (33%), depression (29%) and allergies (18%). Mean MS-related work productivity loss in past 4 weeks was 1.3 days for those without comorbidities and 2.5 days for those with any comorbidity. The annual population costs of work productivity loss were highest for people with depression, allergies, anxiety, migraines and osteoarthritis. Higher number of comorbidities was associated with more work productivity loss and a higher likelihood of not working. These associations were substantially reduced after adjustment for MS symptom severity.

Conclusions:

Comorbidities substantially impact employment outcomes and these effects were mainly mediated through MS symptom severity. This suggests that optimal and simultaneous management of comorbidities may be a viable strategy to reduce MS symptom severity, which in turn could improve employment outcomes.

Keywords

Multiple sclerosis comorbidity symptom depression employment work productivity

Get full access to this article

View all access options for this article.

References

Marrie

Cohen

Stuve

, et al. A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: Overview. Mult Scler 2015; 21(3): 263–281.

Marrie

Patten

Tremlett

, et al. Sex differences in comorbidity at diagnosis of multiple sclerosis: A population-based study. Neurology 2016; 86(14): 1279–1286.

Marrie

RA.

Comorbidity in multiple sclerosis: Implications for patient care. Nat Rev Neurol 2017; 13(6): 375–382.

Tinghog

Bjorkenstam

Carstensen

, et al. Co-morbidities increase the risk of disability pension among MS patients: A population-based nationwide cohort study. BMC Neurol 2014; 14: 117.

Marrie

Fisk

Tremlett

, et al. Differences in the burden of psychiatric comorbidity in MS vs the general population. Neurology 2015; 85(22): 1972–1979.

Tettey

Siejka

Simpson

Jr , et al. Frequency of comorbidities and their association with clinical disability and relapse in multiple sclerosis. Neuroepidemiology 2016; 46(2): 106–113.

Marrie

Horwitz

Cutter

, et al. The burden of mental comorbidity in multiple sclerosis: Frequent, underdiagnosed, and undertreated. Mult Scler 2009; 15(3): 385–392.

Kang

Chen

Lin

HC.

Comorbidities amongst patients with multiple sclerosis: A population-based controlled study. Eur J Neurol 2010; 17(9): 1215–1219.

Brenner

Alexanderson

Bjorkenstam

, et al. Psychiatric diagnoses, medication and risk for disability pension in multiple sclerosis patients: A population-based register study. PLoS ONE 2014; 9(8): e104165.

10.

Chen

Taylor

Palmer

, et al. Estimating MS-related work productivity loss and factors associated with work productivity loss in a representative Australian sample of people with multiple sclerosis. Mult Scler J 2018; 25: 994–1004.

11.

Fiest

Fisk

Patten

, et al. Fatigue and comorbidities in multiple sclerosis. Int J MS Care 2016; 18(2): 96–104.

12.

Fiest

Fisk

Patten

, et al. Comorbidity is associated with pain-related activity limitations in multiple sclerosis. Mult Scler Relat Disord 2015; 4(5): 470–476.

13.

Finlayson

Preissner

Cho

Impact of comorbidity on fatigue management intervention outcomes among people with multiple sclerosis: An exploratory investigation. Int J MS Care 2013; 15(1): 21–26.

14.

Taylor

Palmer

Simpson

Jr , et al. Assessing possible selection bias in a national voluntary MS longitudinal study in Australia. Mult Scler 2013; 19(12): 1627–1631.

15.

Polman

Reingold

Banwell

, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69(2): 292–302.

16.

Reilly

Zbrozek

Dukes

EM.

The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993; 4(5): 353–365.

17.

Reilly

Gooch

Wong

, et al. Validity, reliability and responsiveness of the work productivity and activity impairment questionnaire in ankylosing spondylitis. Rheumatology 2010; 49(4): 812–819.

18.

Wahlqvist

Carlsson

Stalhammar

, et al. Validity of a work productivity and activity impairment questionnaire for patients with symptoms of gastro-esophageal reflux disease (WPAI-GERD) – Results from a cross-sectional study. Value Health 2002; 5(2): 106–113.

19.

Zhang

Bansback

Boonen

, et al. Validity of the work productivity and activity impairment questionnaire – General health version in patients with rheumatoid arthritis. Arthritis Res Ther 2010; 12(5): R177.

20.

Sanderson

Tilse

Nicholson

, et al. Which presenteeism measures are more sensitive to depression and anxiety. J Affect Disord 2007; 101(1–3): 65–74.

21.

Leggett

van der Zee-Neuen

Boonen

, et al. Content validity of global measures for at-work productivity in patients with rheumatic diseases: An international qualitative study. Rheumatology (Oxford) 2016; 55(8): 1364–1373.

22.

Australian Bureau Statistics. Profiles of disability, Australia, 2009. http://www.abs.gov.au/ausstats/abs@.nsf/Lookup/4429.0Main+Features100182009 (2012, accessed December 3 2018).

23.

Learmonth

Motl

Sandroff

, et al. Validation of patient determined disease steps (PDDS) scale scores in persons with multiple sclerosis. BMC Neurol 2013; 13: 37.

24.

Hohol

Orav

Weiner

HL.

Disease steps in multiple sclerosis: A simple approach to evaluate disease progression. Neurology 1995; 45(2): 251–255.

25.

Barros

Hirakata

VN.

Alternatives for logistic regression in cross-sectional studies: An empirical comparison of models that directly estimate the prevalence ratio. BMC Med Res Methodol 2003; 3: 21.

26.

Burke

WJ.

Fitting and interpreting Cragg’s tobit alternative using Stata. Stata J 2009; 9: 584–592.

27.

Raissi

Bulloch

Fiest

, et al. Exploration of undertreatment and patterns of treatment of depression in multiple sclerosis. Int J MS Care 2015; 17(6): 292–300.

28.

Berrigan

Fisk

Patten

, et al. Health-related quality of life in multiple sclerosis direct and indirect effects of comorbidity. Neurology 2016; 86(15): 1417–1424.

29.

Feinstein

Magalhaes

Richard

, et al. The link between multiple sclerosis and depression. Nat Rev Neurol 2014; 10: 507–517.

30.

The Consortium of Multiple Sclerosis Centers. Comorbidities in multiple sclerosis: A clinical resource guide. https://mscomorbidities.com/(2018, accessed 17 September 2018).

31.

Ziebarth

DJ.

Wholistic health care: Evolutionary conceptual analysis. J Relig Health 2016; 55(5): 1800–1823.

32.

Feys

Giovannoni

Dijsselbloem

, et al. The importance of a multi-disciplinary perspective and patient activation programmes in MS management. Mult Scler 2016; 22(2 Suppl.): 34–46.

33.

National Clinical Guideline Centre and National Institute for Health and Care Excellence. Multiple sclerosis: management of multiple sclerosis in primary and secondary care. London: National Institute for Health and Care Excellence, 2014.

34.

Degenhardt

Ramagopalan

Scalfari

, et al. Clinical prognostic factors in multiple sclerosis: A natural history review. Nat Rev Neurol 2009; 5(12): 672–682.

35.

Marrie

Leung

, et al. Rising prevalence of vascular comorbidities in multiple sclerosis: Validation of administrative definitions for diabetes, hypertension, and hyperlipidemia. Mult Scler 2012; 18(9): 1310–1319.

36.

Marrie

Rudick

Horwitz

, et al. Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis. Neurology 2010; 74(13): 1041–1047.